Biomagnetic Technologies of San Diego has formed a joint venture with another firm to develop high-temperature superconductive technology. In forming the joint venture, called Magnesensors, BTI will contribute its clean-room facility and superconducting
Biomagnetic Technologies of San Diego has formed a joint venture with another firm to develop high-temperature superconductive technology. In forming the joint venture, called Magnesensors, BTI will contribute its clean-room facility and superconducting device fabrication processes, while its partner, Quantum Magnetics of San Diego, will add its backlog of R&D contracts in the technology.
BTI and Quantum believe the technology to be developed by Magnesensors could be used for both healthcare and non-healthcare applications. For example, it could be used to monitor heart function of a fetus during pregnancy, or for industrial uses like detecting explosives. Magnesensors will be headed by former BTI veteran Mark Dilorio as president and CEO, and will start with equipment and personnel from both companies.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.